Objectives: This study investigates the therapeutic effect of vitamin C on the development of endometrial lesions and fecundity disorders in the ovarian induction model of mouse endometriosis. Methods: Ovarian endometriosis was surgically induced in 14 NMRI female mice (treatment group, N = 7) and (control group, N = 7). Three days after the second surgery (to assess endometriotic implant), the mice were randomized into two intervention groups: control (placebo) and treatment (50 mg/kg vitamin C every two days orally for four weeks) groups. In the oestrus phase, the mice were sacrificed. In macroscopic assessment, endometriotic implants were evaluated in size, volume, weight, growth score and adhesion score. The microscopic assessment examined the ovarian tissue (the number of antral follicles, corpus luteum and atretic follicles) and endometriotic lesion (histologic and trichrome fibrosis scores). Results: Post-treatment implant volume, growth score, adhesion extent score and adhesion severity score were significantly lower in the treatment group (vitamin C) in comparison with the control group (placebo) (p < 0.0001). The difference between the median weight of endometriotic implants, epithelialization of implant tissue, trichrome fibrosis scores and follicle number in the two groups (treatment and control) was statistically significant (p < 0.05). Atretic follicles were significantly decreased after vitamin C therapy (p < 0.05). Although the numbers of corpus luteum seemed to be more preserved in specimens from the control group, there was no statistical significance between the two groups’ histological scores. Conclusion: As a result, we may imply that vitamin C has a significant effect on reducing the induction and growth of endometrial implants, improving the fecundity function of ovaries, and consequently prevention of endometriosis-associated cancers. Further research is needed to improve targeted interventions resulting in the prevention and treatment of human endometriosis.
Strategies for non-invasive biomarker discovery in early detection of cancer are an urgent need. Extracellular vesicles (EVs) have generated increasing attention from the scientific community and are under intensive investigations due to their unique biological profiles and their non-invasive nature. EVs are membrane-enclosed vesicles with variable sizes and function. Such vesicles are actively secreted from multiple cell types and are considered as key vehicles for inter-cellular communications and signalling. The stability and potential to easily cross biological barriers enable EVs for exerting durable effects on target cells. These along with easy access to such vesicles, the consistent secretion from tumour during all stages of tumorigenesis and their content providing a reservoir of molecules as well as mirroring the identity of the cell of origin are virtues that have made EVs appealing to be assessed in liquid biopsy approaches and for using as a promising resource of biomarkers in cancer diagnosis and therapy and monitoring targeted cancer therapy. Early detection of EVs will guide time-scheduled personalised therapy. Surveying reliable and sensitive methods for rapid isolation of EVs from biofluids, the purity of isolated vesicles and their molecular profiling and marker specification for clinical translation in patients with cancer are issues in the area and the hot topics of many recent studies. Here, the focus is over methods for EV isolation and stratification for digging more information about liquid biopsy-based diagnosis. Extending knowledge regarding EV-based strategies is a key to validate independent patient follow-up for cancer diagnosis at early stages and inspecting the efficacy of therapeutics.
Recently, there is evidence that the coronavirus disease 2019 (COVID-19) increases the risk of venous thromboembolism by creating a prothrombotic state. COVID-19 and pulmonary embolism (PE) are both associated with tachypnoea, hypoxemia, dyspnoea, and increased D-dimer. Diagnosis of pulmonary embolism in a patient with COVID-19 compared to a patient without it using the conventional clinical and biochemical evidence is challenging and somehow impossible. In this study, we report 4 male cases affected by COVID-19, admitted to hospitals in Sanandaj, Iran. The patients were all older adults (ranged between 56 and 95 years of age). Fever, chills, muscle aches, and cough were evident in all of them. Red blood cell levels were low, while pulmonary embolism was clearly seen on spiral computed tomographic (CT) angiography of the pulmonary circulation of all patients. These cases demonstrated that COVID-19 may lead to pulmonary embolism by causing blood coagulation problems. As COVID-19 continues to cause considerable mortality, more information is emerging which reveals its complicated pathogenicity. In the meantime, venous thromboembolism remains an uncommon finding in patients with COVID-19. It is essential that health care providers perform the necessary diagnostic evaluations and provide appropriate treatment for patients.
In December 2019, the World Health Organization (WHO) announced a series of pneumonia cases caused by an unknown origin, discovered in Wuhan, China. A dangerous virus called SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2) caused a disease named acute respiratory syndrome, which was later popularly called coronavirus infection (COVID-19). Patients with acute COVID-19 are at high risk for thrombosis in various blood vessels due to over-coagulation, blood stasis, and endothelial damage. To date, very little research has been done on the number and side effects of thromboembolic disorders in patients with COVID-19. In this study, we report a case with COVID-19, who was hospitalized in one of the hospitals in Sanandaj, Iran. There were symptoms of fever, chills, muscle aches, cough, and tachycardia. Laboratory tests such as CRP, ESR, Ferritin CLIA, LDH and D-Dimer were observed in this patient at a high level. Doppler ultrasound of this patient revealed an abnormal finding, thrombosis in the right greater saphenous vein. This suggests that COVID-19 may lead to other side effects through damage to blood vessels.
Objectives: This review inspects the usage of animal models and the practical solutions of this method for different challenges of endometriosis. The objectives of the study are to determine and compare the histopathology, biomarkers, and development of endometrial lesions in murine homologous and heterologous endometriosis models. Methods: The literature search was performed on PubMed, Scopus, Web Cochrane, and EMBASE from January 1990 to January 2019. Experimental articles in which the establishment of the endometriosis model had been proven through the examination of size, weight, number of implants, adhesion, histologic score, and altered biomarker were eligible for inclusion. Results: Based on type of induction, articles were categorized into two groups: heterologous-induced method (n=5) and autologousinduced method (n=13). In general, in case of establishing the heterologous induction method is less reliable than the autologous induction method. Conclusions: Using human endometrial tissues for endometrial inductions is possible in heterologous models under immunosuppression, which is more suitable for therapeutic studies, but time limitation considerations are mandatory for this type of model. Homologous endometriosis inductions cause larger endometrial lesions, biomarkers, and reproduction rate changes similar to those occurring in humans. Similarities make this method more appropriate for pathogenesis and genetic studies and also observe the impact of endometriosis on the next generation. Choosing an appropriate model for the induction of endometriosis is dependent on the purpose of each study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.